

Lung Cancer Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Market Report | 2023-01-23 | 110 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The lung cancer therapeutics market is projected to register a CAGR of 8.7% during the forecast period (2022-2027).

The COVID-19 pandemic continues to pose a threat to the world, particularly to those who are already suffering from lung disease. Lung cancer patients have faced numerous challenges as a result of the pandemic. According to an article published in September 2020 titled "The impact of the COVID-19 pandemic on lung cancer patients," at the Fifth Affiliated Hospital of Sun Yat-sen University, around 95 patients out of 161 had delayed their return visit in April 2020, and 47 cases were finally designated as having delayed admission during the pandemic and having to discontinue or delay their regular anticancer treatments.

Lung cancer is a lethal lung tumor portrayed by the undisciplined growth of cells in the lung tissues. Cigarette smoking is the principal risk factor for the development of lung cancer. Prolonged exposure to tobacco smoke can also cause lung cancer. The interpretation of lung cancer is confirmed by biopsy, which is carried out using bronchoscopy or CT guidance. Therefore, the treatment of lung cancer can be done by chemotherapy, radiotherapy, immunotherapy, surgery, etc.

In addition, the increasing funding in the field of research and development of new drugs, increasing pollution due to rapid industrialization, and a rise in the number of smokers are some of the reasons for the increasing prevalence of lung cancer. As per the American Cancer Society 2022, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women. Lung cancer is by far the leading cause of cancer death among both men and women, making up almost 25% of all cancer deaths. Besides, according to the 2021 report by the American Lung Association, while the disease remains the leading cause of cancer deaths among both women and men, over the past five years, the survival rate has increased by 14.5% nationally. Hence, all these factors have been driving the growth of the market.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

In May 2021, the United States Food and Drug Administration approved Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer to Janssen Pharmaceutical Companies of Johnson & Johnson. Such product approvals also add to the growth of the studied market over the forecast period.

However, the side effects of drug therapies and the high cost of the therapies have been restraining the market growth.

Lung Cancer Therapeutics Market Trends

Non-small Cell Lung Cancer (NSCLC) is Expected to Dominate the Market

Primary lung cancer is divided into two types: Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the more common of the two types of lung cancer. As per the American Cancer Society 2019, about 80% to 85% of lung cancers are NSCLC. Adenocarcinoma, squamous cell carcinoma, and large cell carcinoma are the three main subtypes of NSCLC. As their treatment and prognoses (outlook) are often similar, these subtypes, which start from different types of lung cells, are grouped together as NSCLC.

As per the article published by the Cancer Treatment Centers of America in January 2022 on lung cancer types, lung adenocarcinoma is the most common form of lung cancer, accounting for 30% of all cases overall and about 40% of all non-small cell lung cancer occurrences. As per the same source, squamous cell lung cancer accounts for about 30% of all non-small cell lung cancers and is commonly associated with smoking. In most cases of NSCLC, large-cell undifferentiated carcinoma accounts for 10% to 15% of all cases. Large-cell undifferentiated carcinoma has a proclivity for rapidly growing and spreading.

According to the American Cancer Society, 236,740 lung and bronchus cancers are likely to be diagnosed in the United States in 2022, with 130,180 deaths. NSCLC is expected to account for about 85% of those cases. Hence, this is likely to create demand for cancer therapeutics over the forecast period.

In October 2021, Food and Drug Administration approved the immunotherapy drug atezlizumab (Tecentriq) as an additional treatment after surgery and chemotherapy for some patients with non-small cell lung cancer (NSCLC). The recent approval of drugs for the treatment of the non-small cell lung cancer are likely to boost the growth of the market during the forecast period.

North America is Expected to Dominate the Lung Cancer Therapeutics Market

The main driver behind the market growth is the increasing number of people suffering from lung cancer. As per the American Society of Clinical Oncology 2021 report, an estimated 235,760 adults (119,100 men and 116,660 women) in the United States were expected to be diagnosed with lung cancer. Lung cancer makes up about 13% of all new cancer diagnoses. Lung cancer is the second most common cancer and the leading cause of cancer death for men and women in the United States. The report had estimated that 131,880 (69,410 men and 62,470 women) deaths from this disease would occur in 2021.

However, North American countries like the United States and Canada have developed and well-structured healthcare systems. These systems also encourage research and development. These policies encourage global players to enter the United States and Canada. As a result, these countries enjoy the presence of many global market players. As high demand is met by the presence of global players in the region, the market is further expected to grow.

Besides, product approval in the United States also contributes to market growth. For instance, in May 2021, Amgen announced that the US Food and Drug Administration (FDA) had approved LUMAKRAS (sotorasib) for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Lung Cancer Therapeutics Market Competitor Analysis

Some of the players operating in the market are AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co., Pfizer Inc., Allergan Inc., Teva Pharmaceutical Industries Ltd, Abbvie Inc., Johnson & Johnson (Janssen Pharmaceuticals), Amgen Inc., and Novartis AG. The majority of the lung cancer therapeutics are being manufactured by the global key players. Market leaders with more funds for research and better distribution systems have established their positions in the market. Moreover, Asia-Pacific is witnessing an emergence of some small players due to a rise in awareness. This has also helped the market grow.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
 - 4.2.1 Increasing Prevalence of Lung Cancer
 - 4.2.2 Rising Pollution due to Rapid Industrialization and Rise in the Number of Smokers
 - 4.2.3 Increasing Funding in the Field of Research and Development of New Drugs
- 4.3 Market Restraints
 - 4.3.1 Side Effects of Drugs
 - 4.3.2 High Cost of Therapies
- 4.4 Porter's Five Force Analysis
 - 4.4.1 Threat of New Entrants
 - 4.4.2 Bargaining Power of Buyers/Consumers
 - 4.4.3 Bargaining Power of Suppliers
 - 4.4.4 Threat of Substitute Products
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

- 5.1 By Disease Type
 - 5.1.1 Non-small Cell Lung Cancer (NSCLC)
 - 5.1.2 Small Cell Lung Cancer (SCLC)
- 5.2 By Treatment
 - 5.2.1 Chemotherapy
 - 5.2.2 Radiation Therapy

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.2.3 Immunotherapy
- 5.2.4 Targeted Therapy
- 5.2.5 Other Treatments
- 5.3 Geography
 - 5.3.1 North America
 - 5.3.1.1 United States
 - 5.3.1.2 Canada
 - 5.3.1.3 Mexico
 - 5.3.2 Europe
 - 5.3.2.1 Germany
 - 5.3.2.2 United Kingdom
 - 5.3.2.3 France
 - 5.3.2.4 Italy
 - 5.3.2.5 Spain
 - 5.3.2.6 Rest of Europe
 - 5.3.3 Asia-Pacific
 - 5.3.3.1 China
 - 5.3.3.2 Japan
 - 5.3.3.3 India
 - 5.3.3.4 Australia
 - 5.3.3.5 South Korea
 - 5.3.3.6 Rest of Asia-Pacific
 - 5.3.4 Middle-East
 - 5.3.4.1 GCC
 - 5.3.4.2 South Africa
 - 5.3.4.3 Rest of Middle-East
 - 5.3.5 South America
 - 5.3.5.1 Brazil
 - 5.3.5.2 Argentina
 - 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

- 6.1 Company Profiles
 - 6.1.1 AstraZeneca
 - 6.1.2 Boehringer Ingelheim
 - 6.1.3 Bristol-Myers Squibb Company
 - 6.1.4 Eli Lilly and Company
 - 6.1.5 Hoffmann-La Roche
 - 6.1.6 Merck & Co.
 - 6.1.7 Pfizer Inc.
 - 6.1.8 Teva Pharmaceutical Industries Ltd.
 - 6.1.9 Abbvie (Allergan)
 - 6.1.10 Johnson & Johnson (Janssen Pharmaceuticals)
 - 6.1.11 Amgen Inc.
 - 6.1.12 Novartis AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

**Lung Cancer Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts
(2023 - 2028)**

Market Report | 2023-01-23 | 110 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|--------------------------|-----------|
| | Single User License | \$4750.00 |
| | Team License (1-7 Users) | \$5250.00 |
| | Site License | \$6500.00 |
| | Corporate License | \$8750.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2026-02-27"/> |
| | | Signature | |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

